cd38

CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies PURPOSE CD38 is a glycoprotein highly specific to multiple myeloma (MM). Therapeutics using antibodies targeting CD38 have shown promising efficacy. However, the...

Causal Relationship Between Diet, Lipids, Immune Cells, and Chronic Fatigue Syndrome: A Two-Mediation Mendelian Randomization Study Jixu Li, Qi Qin, Yiran Zhu, Yulu Qian, Jialu Yin, Xin Gao, Huijuan Wen, Pei Wang [Line breaks added] Abstract Chronic fatigue syndrome (CFS) is a disorder...

https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1607353/abstract Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urgent need for elucidation of disease mechanisms...

The ME/CFS research team at Haukeland University Hospital in Bergen, Norway (Fluge, Mella, Rekeland, Sørland etc) is recruiting 66 participants for a new placebo-controlled trial on Daratumumab as a potential treatment for ME/CFS. The duration for participants is 72 weeks. The participants will...

Commercialisation of HLX15 (daratumumab) https://www.businesswire.com/news/home/20250206161649/en/Dr.-Reddy’s-enters-into-collaboration-with-Henlius-for-commercialization-of-HLX15-daratumumab-a-biosimilar-candidate-to-Darzalex®-Darzalex-Faspro®-in-the-U.S.-and-Europe

Summary Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma cells and is approved for the treatment of multiple myeloma. Long-lived plasma cells are implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies, but they are...